Astrana Health (NASDAQ:ASTH) Updates FY24 Earnings Guidance

Astrana Health (NASDAQ:ASTH - Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share guidance of $1.12-1.36 for the period, compared to the consensus earnings per share estimate of $1.48. The company issued revenue guidance of $1.75-1.85 billion, compared to the consensus revenue estimate of $1.76 billion.

Analyst Ratings Changes

ASTH has been the subject of a number of recent analyst reports. Robert W. Baird assumed coverage on Astrana Health in a research report on Thursday, May 30th. They set an outperform rating and a $54.00 price objective for the company. Truist Financial raised shares of Astrana Health from a hold rating to a buy rating and boosted their price target for the company from $44.00 to $50.00 in a research note on Thursday, July 11th. Stifel Nicolaus upped their price objective on shares of Astrana Health from $48.00 to $60.00 and gave the stock a buy rating in a report on Thursday, August 1st. Finally, Baird R W upgraded shares of Astrana Health to a strong-buy rating in a report on Thursday, May 30th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Astrana Health presently has an average rating of Buy and an average price target of $53.50.

Read Our Latest Report on Astrana Health

Astrana Health Stock Down 2.6 %

NASDAQ:ASTH traded down $1.22 on Wednesday, reaching $46.36. 231,696 shares of the company's stock were exchanged, compared to its average volume of 173,302. The stock has a market cap of $2.60 billion, a price-to-earnings ratio of 36.03, a price-to-earnings-growth ratio of 1.83 and a beta of 1.16. Astrana Health has a 52-week low of $28.86 and a 52-week high of $54.27. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.56. The business has a fifty day simple moving average of $43.96.

Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its earnings results on Tuesday, May 7th. The company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). The business had revenue of $404.36 million for the quarter, compared to analysts' expectations of $413.84 million. Astrana Health had a return on equity of 10.22% and a net margin of 4.29%. Astrana Health's quarterly revenue was up 19.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.42 earnings per share. As a group, equities analysts anticipate that Astrana Health will post 1.42 earnings per share for the current year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.

Further Reading

• Five stocks we like better than Astrana Health
• Compound Interest and Why It Matters When Investing
• What Are Bonds? A High-Level Overview
• The 3 Best Retail Stocks to Shop for in August
• Super Micro Stock Drops Sharply After Earnings on Margin Concerns
• Utilities Stocks Explained – How and Why to Invest in Utilities
• Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Secure Your Wealth: Free Digital Dollar Guide from Colonial Metals Group! (From Colonial Metals) (Ad)

Should you invest $1,000 in Astrana Health right now?

Before you consider Astrana Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.

While Astrana Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here